<DOC>
	<DOCNO>NCT00334256</DOCNO>
	<brief_summary>To study pharmacokinetic property , safety viral resistance pattern combination tenofovir disoproxil fumarate emtricitabine HIV-1-infected pregnant woman newborn , view prevention mother-to-child transmission ( PMTCT ) HIV-1 Africa Asia .</brief_summary>
	<brief_title>Tenofovir/Emtricitabine PMTCT Africa Asia ( ANRS 12109 TEmAA )</brief_title>
	<detailed_description>Single-dose nevirapine ( sdNVP ) option choice prevention mother-to-child transmission ( PMTCT ) HIV-1 country limit resource . However , use sdNVP result resistance mutation estimate frequency least 15 70 % woman W4-W6 postpartum . These mutation could compromise success subsequent treatment mother child antiretroviral combination include NVP . Pre-clinical clinical study suggest combination TDF FTC , drug interest pharmacokinetic property may useful alternative complement sdNVP . The objective study pharmacokinetic property , safety viral resistance pattern combination tenofovir disoproxil fumarate { TDF , 600 mg } emtricitabine { FTC , 400 mg } ) HIV-1-infected pregnant woman newborn , view prevention mother-to-child transmission ( PMTCT ) HIV-1 Africa Asia . Phase II trial , multicentre , open-label conduct two step 30 mother-infant pair per step balance allocation Abidjan ( Côte d'Ivoire ) , Soweto ( South Africa ) Phnom Penh ( Cambodia ) : Step 1 : administration TDF/FTC mother ; Step 2 : administration TDF/FTC mother newborn .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>Women receive voluntary counsel test know serological status HIV1 HIV1+2 infection whose serological diagnosis confirm two sample Aged 18 year day inclusion Ongoing pregnancy 28 38 week gestation day inclusion . This estimate base date last menstruation , ultrasound scan , uterine height measurement Indication antiretroviral treatment Prevention MotherToChildTransmission ( PMTCT ) , line international national recommendation force : WHO 's clinical stage 1 , 2 CD4≥200/mm3or stage 3 CD4≥350/mm3 ( No indication antiretroviral treatment ) Haemoglobin 8 g/dL month precede inclusion Blood creatinine less three time upper limit normal value Creatinine clearance &gt; 49 mL/min Transaminases ( ALAT ASAT ) less five time upper limit normal value Neutrophils ≥750/mm3 No hypersensitivity emtricitabine , tenofovir , tenofovir disoproxil fumarate , zidovudine , nevirapine excipients Signed informedconsent form woman , father child bear Planned delivery hospital set stay least 72 hour afterwards Agreement take medication trial without tell investigator Naïve antiretroviral treatment antiretroviral prophylaxis PMTCT previous pregnancy Permanent residence close enough study centre enable followup stipulate protocol Under 18 year age Infected HIV2 alone One two parent ( father ) refuse sign consent participate ( available Abidjan Phnom Penh ) mother ( Soweto site ) Indication antiretroviral treatment ( stage 4 CD4 &lt; 200/mm3 stage 3 CD4 &lt; 350/mm3 ) Has already take antiretrovirals , include exposure previous treatment prophylaxis PMTCT , inclusion study Use drug interfere study : nephrotoxic drug amphotericin B , ganciclovir , valganciclovir cidofovir , foscarnet , aminosides , pentamidine , cisplatin anticoagulant ( heparin ) Regular use drug alcohol Health problem require systematic treatment hospitalization Severe pregnancy disease ( preeclampsia ) lifethreatening mother , infant , Severe vomit prevent ingestion tablet Refuses give birth study site stay hospital least 72 hour afterwards Renal insufficiency define blood creatinine three time upper limit normal value Creatinine clearance equal 49 mL/min Hepatic insufficiency define transaminase ( ALAT ASAT ) five time upper limit normal value Neutrophils &lt; 750/mm3 Haemoglobin &lt; 8 grams/dL month precede inclusion Hypersensitivity emtricitabine , tenofovir , tenofovir disoproxil fumarate , zidovudine , nevirapine excipients</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>PMTCT</keyword>
	<keyword>Resistance</keyword>
	<keyword>HIV infection</keyword>
	<keyword>Pregnancy</keyword>
</DOC>